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Abstract: Background: Paediatric acute hematogenous osteomyelitis (AHOM) is a serious disease
requiring early diagnosis and treatment. To review the clinical presentation, management and
organisms responsible for AHOM, and to explore risk factors for complicated AHOM, a large
cohort referring to a single center over a 6-year period was evaluated. Methods: Data from children
with AHOM, hospitalized between 2010 and 2015, and aged > 1 month, were retrospectively
collected and analyzed. Results: 121 children (median age 4.8 years; 55.4% males) were included.
Fever at onset was present in 55/121 children (45.5%); the lower limb was most frequently affected
(n = 68/121; 56.2%). Microbiological diagnosis (by culture and/or polymerase chain reaction (PCR))
was reached in 33.3% cases. Blood and pus/biopsy culture sensitivities were 32.4% and 46.4%,
respectively. PCR sensitivity was 3.6% (2/55) on blood, and 66.6% (16/24) on pus/biopsy sample.
Staphylococcus aureus was the most commonly identified pathogen (n = 20); no methicillin-resistant
Staphylococcus aureus (MRSA) was isolated, 10.0% (n = 2) strains were Panton-Valentine-Leukocidin
(PVL) producer; 48.8% (59/121) cases were complicated. At univariate analysis, factors associated
with complicated AHOM were: recent fever episode, fever at onset, upper limb involvement,
white blood count (WBC) ≥ 12,000/µL, C reactive protein (CRP) ≥ 10 mg/L, S. aureus infection.
At multivariate analyses S. aureus infection remained the only risk factor for complicated AHOM
(aOR = 3.388 (95%CI: 1.061–10.824); p-value = 0.039). Conclusions: In this study microbiological
diagnosis was obtained in over one third of cases. Empiric treatment targeting methicillin-sensitive
Staphylococcus aureus seems to be justified by available microbiological data.
Keywords: acute haematogenous osteomyelitis; children; antibiotic therapy; outcome
1. Introduction
Most acute pediatric osteomyelitis are haematogenous infections with an estimated incidence of
8 cases per 100,000 children/year [1,2]. Children below 5 years of age and males are more frequently
affected [3]. Early detection of acute hematogenous osteomyelitis (AHOM) is crucial, given that
a delay in the diagnosis of only 5 days is a major risk factor for complications [4]. Even if mortality
is rare, permanent disabilities can occur, such as growth arrest with limb length discrepancy or
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deformity [5]. AHOM etiology is changing according to bacterial susceptibility pattern modifications
over time, vaccination programs, and implementation of cultural and polymerase chain reaction (PCR)
techniques. Staphylococcus aureus (S. aureus) is the most commonly isolated pathogen [6], accounting
for 25–60% of cases of AHOM. Other microorganisms include Group-A Streptococcus pyogenes,
Streptococcus pneumoniae, and Gram-negative rods [5]. Kingella kingae is an emergent pathogen [4,7].
Infections sustained by community acquired methicillin resistant S. aureus (MRSA) are increasing,
particularly in the United States [8]. On the other hand, in Europe community acquired-MRSA is
still identified at low rates, while Panton-Valentine-Leukocidin (PVL) producing S. aureus isolates are
increasingly reported [9]. The empirical therapeutic choice is based on local epidemiological data [4].
An anti-staphylococcal penicillin, i.e., oxacillin or flucloxacillin, or a cephalosporin are generally
recommended as first line treatment [4]. Some expert suggest the use of other drugs, including
antibiotics effective towards MRSA, depending on local MRSA prevalence [10]. The duration and
routes of administration of antibiotics is currently under debate [11]. Historically, AHOM was treated
with intravenous (IV) antibiotics for several weeks [12]. More recently, a randomized trial showed
that children who displayed a good clinical response after 2–4 days of IV treatment and shifted to oral
treatment for further 20 days had not different outcomes when compared to children treated with
continued IV therapy for 30 days [13]. A similar approach, using a short IV therapy (about 7 days)
has been adopted by several centers in Europe [14] and USA [15], suggesting that short IV therapy
may be as effective as longer courses with no increased risk of sequelae. Given the changes in
immunization programs, the emergence of MRSA, availability of molecular diagnostics and changing
trends in management, a review of the epidemiology of this important disease is needed. Therefore,
we evaluated data from a large cohort of otherwise healthy children referring to a single center over
a 6-year period.
2. Methods
Aim of the present study was to evaluate retrospectively the management and outcome of AHOM
in a large single tertiary center over a 6-year period, with particular consideration to possible risk
factors for complicated AHOM.
2.1. Setting
Meyer Children’s Hospital is a tertiary pediatric university hospital with 200 beds and serves as
the main referral center for Tuscany and surrounding regions [16]. The hospital comprises several
paediatric departments, including general orthopedic, surgical, intensive care, infectious diseases and
other specialist units, working in a multidisciplinary team. Tuscany has a population of three million
and six hundred thousand people, 6.2% of the Italian population, with 565,886 people under the age of
18 years [16].
2.2. Definitions
AHOM was defined as any bone infection presenting with a time period between diagnosis and
symptom onset <2 weeks [10,17]. AHOM was diagnosed in the presence of clinical features (fever,
swelling, warmth, pain, restriction of movement) and compatible radiologic imaging with or without
bacteriological isolation from blood or bone sample [14].
2.3. Complicated Osteomyelitis
AHOM was defined as complicated when the child developed sepsis, septic shock, or arthritis,
cellulitis, sub-periosteal or muscle abscess, deep venous thrombosis (DVP) [14], pathologic fracture,
septic emboli or when the child necessitated admission to the intensive care unit (ICU) [4].
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2.4. Study Design and Population
A retrospective single center study was conducted, evaluating data from all children aged between
1 month and 18 years, consecutively admitted to Meyer Children’s Hospital with a discharge code
consistent with the diagnosis of osteomyelitis (ICD codes M86.00-86.99) , according to the World Health
Organization International Classification of Diseases (WHO ICD-10), between 1 January 2010 and
31 December 2015. Data from these children were independently reviewed by two authors. Inclusion
criteria was AHOM, as defined above, and exclusion criteria were: age ≤ 30 days; congenital or
acquired immunodeficiency, underlying bone disease; carrier of prosthetic materials; hospital acquired
infection, previous history of skin wound, open fracture or surgery at the site of bone infection or
in contiguous areas, septic arthritis (i.e., no adjacent osteomyelitis on imaging). Only cases fulfilling
the above criteria were included in the study. Data were collected from medical records, electronic
records for laboratory, and radiology results. Demographic and clinical details, microbiological and
radiologic results, and clinical management including type, route and duration of antibiotic treatment,
need for surgery, and readmission to hospital within 6 months of initial diagnosis were entered into
an electronic database. Reasons for changes in the antibiotic regimen were also recorded (i.e., clinical
and/or radiological failure; switch from IV to oral therapy; drug toxicity; switch from empirical
therapy to a targeted antimicrobial therapy after bacterial isolation).
Surgery was performed in children not responding to medical treatment, or needing draining
an abscess or in children with adjacent arthritis needing draining and joint lavage.
2.5. Laboratory and Microbiological Investigations
All the laboratory tests were performed in the same laboratory at the Author’s Institution using
standardized techniques and according to manufacturer’s instructions. Hematological parameters
(WBC, CRP, ESR) were collected at admission before administration of any antimicrobial therapy.
In particular CRP in serum or heparinized plasma was detected by means of particle enhanced
immunonephelometry on the Dimension Vista™ System equipped with the Dimension Vista™
System Flex® reagent cartridge (Siemens Healthcare Diagnostics, Marburg, Germany). The Analytical
Measurement Range (AMR) is 0.29–19.0 mg/dL. ESR was measured using a capillary micro-photometer
method, and expressed in mm/hour. The AMR is 2–120 mm/h.
Blood cultures and cultures from bone or joint fluid samples were processed using standard
methods. All samples were processed for detection of common human bacteria (or cultured for
detection of MRSA isolates) using rich and selective culture media. After 48 hours of incubation
in aerobic atmosphere at 37 ◦C, plates were read in order to detect the presence of pathogens.
Identification of bacteria isolates was based on typical colony morphology on selective culture media
(Mannitol Salt 2 Agar, Mac Conkey Agar, bioMérieux, (Geneva, Switzerland)) or on chromogenic
culture media (chromID® CARBA SMART, bioMérieux and BBL™ CHROMagar™ MRSA II, Becton
Dickinson, (Becton Dickinson, Lincoln Park, NJ, USA). In order to confirm species-level identification
mass spectrometry analysis was performed using MALDI-TOF (VITEK® MS, bioMérieux). Organisms
were identified phenotypically and confirmed using traditional methods or the Vitek2 gram positive
card (bioMérieux). Antibiotic susceptibility testing was performed using an automated system (Vitek2
AST-P612 card, bioMérieux) and the Kirby–Bauer disk diffusion method in accordance with the
guidelines of the Clinical and Laboratory Standards Institute. Antibiotic susceptibility was evaluated
using the automated system VITEK®2 (bioMérieux) with the card AST-P632 for the several antibiotics.
The European committee on antimicrobial susceptibility testing (EUCAST) clinical breakpoints were
used as interpretation criteria. The pathogenicity of S. aureus infections is related to various bacterial
surface components and to extracellular proteins such as PVL. In order to determine the potential
virulence of MRSA strains, a specific PCR assay for the presence of the gene (lukS-lukF) encoding for
the PVL was set up following a previously published protocol [18].
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Universal real-time PCR assay targeting the gene coding for 16S ribosome RNA coupled with
sequencing of amplified products was performed on blood and/or tissue samples, as previously
described [19,20].
2.6. Statistical Methods
Data were reported as median and interquartile range (IQR) or absolute numbers and percentages.
Non parametric Mann-Whitney test, Fisher’s exact test or Chi Square test were used to compare
continuous or categorical variables, as appropriate. All significant tests were two-sided. Uni- and
multi-variate logistic regression analyses were performed to investigate the association between
several parameters and risk of complicated AHOM, calculating odds ratios (ORs) and 95% confidence
intervals (CIs). Variables included in univariate analyses were gender, age, site of infection (upper limb,
lower limb, other site), previous trauma, previous fever episode, clinical characteristics at the
time of admission, WBC (≥ or <12,000 cell/µL) CRP (≥ or <10 mg/L), ESR (≥ or <20 mm/h);
initial X-ray (positive or negative); initial ultrasound (US) (positive or negative); initial MRI (positive or
negative); positive microbiological culture or PCR on blood or pus; infection sustained by S. aureus vs.
other/unknown; first antibiotic treatment duration (≥ or <10 days) and type of first antibiotic regimen.
Factors significantly associated to complicated AHOM at univariate analysis were included in the
multivariate analyses. All statistical analyses were carried out using the SPSS (Statistical Package
for the Social Sciences, SSPS Inc., Chicago, IL, USA) for Windows software program version 19.0.
A p-value < 0.05 was considered significant. The study was approved by the Ethics Committee at the
authors’ institution (121/2016).
3. Results
Overall, 121 children were included in the study (Table 1). Median age was 4.8 years
(IQR: 1.6–10.5); 67/121 (55.4%) children were males; 117/121 (96.7%) children were Caucasian;
2/121 (1.6%) children were Asian and 2/121 (1.6%) were Hispanic. Thirteen out of 121 (10.7%)
children were immigrants (born abroad). None of the children had a positive history for recent travel.
Previous trauma (within 15 days) was reported in 25/121 children (20.7%). Ten children participated
in sport activities (8.3%); 66/121 (54.5%) had a recent episode of fever. Median interval between
symptom onset and hospital admission was 6 days (IQR: 2–12) and 60 children (49.6%) were admitted
5 days after symptom onset. Fever at presentation was present in 55/121 children (45.5%) while
117/121 (96.7%) displayed at least one inflammation sign. In particular, 67/121 children (55.4%)
presented with swelling, 58/121 (47.9%) with increased warmth, 111/121 (91.7%) with pain and
45/121 (37.2%) with erythema at the affected site; 97/121 (80.2%) had functional limitation.
The lower limb was most frequently affected (n = 68/121; 56.2%), followed by the upper limb
(n = 21/121; 17.4%). Localization was on long bones in 68/121 (56.2%) of cases. The metaphysis was
involved in 43 cases (68%), the diaphysis in 6 (8.8%). Extension of the infection from the metaphysis to
the diaphysis was observed in 19 cases (27.9%), while an epiphyseal involvement was observed in
12/68 (17.6%). The pelvis was involved in 15 cases (12.3%) and there were seven discitis (5.7%).
Fifty-nine children out of 121 (48.8%) had a complicated AHOM. In particular, 4/121 (3.3%)
children developed deep vein thrombosis (DVT); 22/121 (18.2%) sepsis/septic shock, 32/121 (26.4%)
arthritis, 20/121 (16.6%) cellulitis, 16/121 (13.2%) sub-periosteal abscess, 13/121 (10.7%) muscle
abscess, 5/121 (4.13%) pathologic fracture, 2/121 (1.7%) septic emboli and 7/121(5.8%) needed to be
admitted to ICU.
With respect to uncomplicated cases, complicated cases more frequently involved the upper limb
(27.1% vs. 8.1%; p-value = 0.005) and more frequently reported a recent episode of fever (69.5% vs.
40.3%; p-value = 0.001). We observed a higher proportion of complications when long bone were
involved vs. non long bone (p-value = 0.021). Children with complicated AHOM presented more
frequently fever at onset (59.3% vs. 32.3%; p-value = 0.002) (Table 1). Other factors associated with
complications were, WBC ≥ 12,000/µL, CRP ≥ 10 mg/L, a positive microbiological test, infection
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sustained by S. aureus and a positive MRI. In the multivariate analyses only infection sustained by
S. aureus was associated with risk of complicated AHOM (OR = 3.388 (1.061–10.824); p-value = 0.039)
(Table 2).











Female 54 30 (48.4%) 24 (40.7%) 0.393
Male 67 32 (51.6%) 35 (59.3%)
Ethnicity (n; %)
Caucasian 117 59 (95.2%) 58 (98.3%) 0.619 (vs. others)
Asian 2 2 (3.2%) 0 (0.0%)
Hispanic 2 1 (1.6%) 1 (1.7%)
Median age (months; IQR) 59 (21–125) 58 (17–130) 0.669
Interval between symptom
onset and diagnosis (days; IQR) 5 (2–11) 7 (5–10) 0.671
Median length of total
antibiotic therapy
(IV plus oral) (days; IQR)
35 (30–39) 41 (31–48) 0.037
Recent travel (n; %) Yes 0 0 (0.0%) 0 (0.0%)
Recent Trauma (n; %) Yes 25 (20.7%) 10 (16.1%) 15 (25.4%) 0.206
Involved bone
(Grouped Site) (n; %)
Upper limb 21 (17.4%) 5 (8.1%) 16 (27.1%) 0.008
Lower limb 68 (56.2%) 35 (56.5%) 33 (55.9%) 0.954
Other 32 (26.4%) 22 (35.5%) 10 (16.9%) 0.021
Site (n; %)
Humerus 13 (10.7%) 3 (4.9%) 10 (16.9%) 0.040
Ulna 3 (2.5%) 0 (0.0%) 3 (5.1%)
Radius 1 (0.8%) 0 (0.0%) 1 (1.7%)
Clavicle 2 (1.7%) 1 (1.6%) 1 (1.7%)
Scapula 1 (0.8%) 0 (0.0%) 1 (1.7%)
Carpal bones 1 (0.8%) 1 (1.6%) 0 (0.0%)
Phalanges of the hand 2 (1.7%) 1 (1.6%) 1 (1.7%)
Mandible 1 (0.8%) 1 (1.6%) 0 (0.0%)
Skull bones 1 (0.8%) 1 (1.6%) 0 (0.0%)
Ribs 2 (1./%) 2 (3.2%) 0 (0.0%)
Vertebrae 11 (9.1%) 9/62 (14.5%) 2 (3.4%)
Hip 16 (13.2%) 9 (14.5%) 7 (11.9%)
Femur 19 (15.7%) 5 (8.1%) 14 (23.7%) 0.023
Patella 1 (0.8%) 0 (0.0%) 1 (1.7%)
Tibia 17 (14.0%) 8 (12.9%) 9 (15.2%)
Fibula 3 (2.5%) 1 (1.6%) 2 (3.4%)
Tarsus bone 23 (19.0%) 17 (27.4%) 6 (10.2%) 0.015
Metatarsus and
phalanges of the foot 6 (5.0%) 5 (8.1%) 1 (1.7%)
Multifocal AHOM (n; %) Yes 6 (5.0%) 3 (4.8%) 3 (5.1%) 1.000
Sport (n; %) Yes 10 (8.3%) 1 (1.6%) 9 (15.3%) 0.007
Recent episode of fever (n; %) Yes 66 (54.5%) 25 (40.3%) 41 (69.5%) 0.001
Fever at onset (n; %) Yes 55 (45.5%) 20 (32.3%) 35 (59.3%) 0.002
At least an inflammation sign
at onset (n; %) Yes 117 (96.7%) 59 (95.2%) 58 (98.3%) 0.619
Swelling (n; %) Yes 67 (55.4%) 29 (46.8%) 38 (54.4%) 0.051
Warmth (n; %) Yes 58 (47.9%) 23 (37.1%) 35 (59.3%) 0.014










Pain (n; %) Yes 111 (91.7%) 54 (87.1%) 57 (96.6%) 0.095
Redness (n; %) Yes 45 (37.2%) 16 (25.8%) 29 (49.2%) 0.007
Biopsy executed (n; %) Yes 22 11 (16.1%) 11 (18.6%) 0.745
Positive blood PCR (n; %) Yes 3/55 (5.5%) 1/21 (4.8%) 2/34 (5.9%) 1
Positive pus/biopsy PCR (n; %) Yes 17/25 (68.0%) 5/7 (71.4%) 12/18 (66.7%) 1
Positive blood culture (n; %) Yes 15/37 (40.5%) 1/15 (6.7%) 14/15 (93.3%) 0.108
Staphylococcus aureus
positivity (n; %) Yes 20/72 (27.8%) 3/29 (10.3%) 17/43 (39.5%) 0.006
Note: AHOM: acute hematogenous osteomyelitis.









Yes 41/66 (62.1%) 2.197 (1.058–4.564) 0.035 1.541 (0.641–3.707) 0.334
Fever at onset
Yes 35/55 (63.6%) 2.308 (1.111–4.795) 0.025 1.086 (0.439–2.687) 0.859
Grouped Site
Lower limb/other 43/100 (48.5%) 1 1
Upper limb 16/21 (76.2%) 2.444 (1.909–6.573) 0.007 1.7 (0.565–5.111) 0.345
WBC ≥ 12,000/µL
Yes 29/47 (61.7%) 2.363 (1.117–4.998) 0.024 1.873 (0.801–4.379) 0.148
CRP ≥ 10 mg/L
Yes 47/74 (63.5%) 2.774 (1.234–6.238) 0.014 1.771 (0.718–4.370) 0.215
Staphylococcus aureus
Yes 17/20 (85.0%) 4.614 (1.577–13.504) 0.005 3.388 (1.061–10.824) 0.039
Note: factors not significantly associated with complication at univariate analysis were: gender, age < 3 years,
presence of swelling, warmth, pain, redness, ESR > 20 mm/h; IV therapy < 10 days; type of antibiotic regimen.
3.1. Inflammatory Indices
WBC < 12,000/µL was detected in 68/115 (59.1%) patients; 28/68 (41.2%) were complicated and
40/68 (58.8%) uncomplicated children (p-value = 0.030). ESR <20 mm/h was observed in 27/96 (28.1%)
children; 15/27 (55.6%) were complicated and 12/27 (44.4%) uncomplicated (p-value = 0.495).
CRP < 10 mg/L was observed in 39/113 (34.5%) children; 11/39 (28.2%) were complicated and
28/39 (71.8%) uncomplicated (p-value < 0.001).
3.2. Microbiological Tests
Overall, 72/121 (59.5%) children underwent at least one microbiological test (cultures or PCR
assay on blood or bone sample): a pathogen was isolated in 24/72 cases (33.3%).
A blood culture was performed in 37/121 children (30.6%) and it resulted positive in 12/37 cases
(32.4%). A culture of the pus/biopsy was done in 28/121 children (23.1%) and a pathogen was isolated
in 13/28 of them (46.4%). PCR assay on blood samples was performed in 55/121 (45.5%) cases and
was positive only twice (3.6%). PCR assay on pus/biopsy samples was performed in 24/121 (19.8%)
children and was positive in 16/24 (64.0%). In complicated cases the number of positive cultures/PCR
was significantly higher than in uncomplicated cases (complicated 21/27 (77.8%); vs. uncomplicated
6/27 (22.2%); p-value < 0.001).
S. aureus was by far the most common observed pathogen, detected with culture in 20/72 (27.8%)
tested children. It was isolated from 11/15 (73.3%) positive blood cultures, 10/13 (76.9%) positive
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pus/biopsy cultures, 1/2 (50.0%) positive PCR on a blood sample and 12/16 (75.0%) positive
PCR on a pus/biopsy sample. Among those tested, 17/43 (39.5%) of complicated AHOM and
3/29 (10.3%) of uncomplicated were positive for S. aureus respectively (p = 0.006) Two out of
20 (10.0%) S. aureus strains were positive for PVL, and all (20/20; 100%) were methicillin-sensitive.
There was only one isolate with aminoglycoside resistance but susceptibilities to clindamycin,
levofloxacin, and trimethoprim-sulphametoxazole (TMP-SMX) were preserved along with oxacillin
susceptibility. Combined clindamycin and erythromycin resistance was reported in three isolates that
maintained susceptibilities to oxacillin, TMP-SMX, aminoglycosides and levofloxacin. One isolate
showed resistance to TMP-SMX, levofloxacin and erythromycin while maintaining oxacillin and
clindamycin susceptibility.
Other organisms isolated were: Streptococcus pyogenes in 1/15 (6.7%) blood culture and 1/13 (7.7%)
cultures on pus and 2/16 (12.5%) PCR on a pus sample; Proteus mirabilis in 1/13 (7.7%) culture on
pus, Pseudomonas aeruginosa in 1/13 (7.7%) pus cultures, Streptococcus agalactiae in 1/2 (50.0%) PCR
on a blood sample, Fusobacterium necrophorum in 1/16 (6.3%) PCR on a pus sample and Streptococcus
pneumoniae in 1/16 (6.3%) PCR on a pus sample (Table 3). No Kingella kingae isolate was found.
Table 3. Antibiotic therapy in complicated and uncomplicated acute osteomyelitis.
Antibiotic Therapy Complicated AcuteOsteomyelitis (n = 59)
Uncomplicated Acute
Osteomyelitis (n = 62)
IV therapy; days (median and IQR) 20 (12–24) 20 (12–23)
Oral therapy; days (median and IQR) 13 (4–15) 13 (1–14)
Total treatment; days (median and IQR) 36 (30.5–44.5) 36 (30–44.75)
IV Drugs
Single therapy 0 3
Combination therapy 59 59
Oral therapy
Single therapy 44 36
Combination therapy 5 4
The cases with PVL-positive S. aureus infection were two females, aged 3 and 9 years, who developed
AHOM complicated by sub-periosteal abscess in one case and necrotizing pneumoniae and septic
shock, admission to ICU, in the other. Both patients required prolonged IV therapy with second-line
antibiotics and surgery. The older child developed a sequela (angular deformity).
3.3. Imaging Studies
Conventional radiography was performed in 102/121 patients (84.3%). The diagnostic yield of
conventional radiography was low (n = 7/102; 6.9%). US was performed in 64/121 children (52.9%),
and displayed a compatible image only in 5/64 children (7.8%). MRI was performed in 111/121
cases (91.7%) and findings supportive of OM were evidenced in 104/111 cases (93.7%). CT was
marginally used (10/121 children (8.3%)) and findings supportive of OM were present in 6/10 (60.0%).
Bone scintigraphy was performed in 5/121 children (4.1%), with supportive findings of OM in all cases.
3.4. Medical and Surgical Treatment
All the 121 children received IV antibiotics at admission (Table 3). The most frequently
administered antibiotic regimen was the combination oxacillin plus one cephalosporin (91/121; 75.2%),
followed by a glycopeptide based therapy (n = 12/121; 9.9%) and a clindamycin based therapy
(n = 5/121; 4.1%).
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In 64/121 (52.9%) the first therapy was switched to a second IV antibiotic regimen for the following
reasons: clinical failure (9/64 children; 14.1%), targeted therapy after pathogen identification (12/64;
18.8%), allergic reaction (6/64; 9.4%), simplification from a double therapy to a single-drug therapy
(28/64; 43.8%). Reason was not specified in 9 cases (14.1%)
Twenty-two out of 27 (77.8%) children with at least a positive microbiological test switched to
a second IV treatment; 18/22 (81.8%) with complicated AHOM and 4/22 (18.2%) with uncomplicated
AHOM (p-value = 0.303). Seven out of 22 (31.8%), all complicated, switched to a second IV therapy for
a clinical failure; 9/22 (40.9%) switched to a target therapy after receiving result of microbiological
tests, 1/22 (4.5%) passed to a second IV therapy for allergic reaction and 5/22 (22.7%) switched for
therapeutic simplification.
Eighty-eight out of 121 (72.7%) children switched to an oral antibiotic therapy; most commonly
amoxicillin/clavulanic (69/88; 78.4%). Other used oral antibiotics were clindamycin (n = 4),
ciprofloxacin (n = 3), linezolid (n = 3). Overall 20/121 (16.5%) children underwent surgery, 15/20 (75.0%)
with a complicated osteomyelitis and 5/20 (15.0%) with a uncomplicated (p-value: 0.002); 7/121 (5.8%)
children underwent surgery for two times.
3.5. Follow-Up Results
9/121 (7.4%) children were switched to a second IV therapy for clinical failure with subsequent
complete resolution; 4 children out of 121 (3.3%) were hospitalized twice for clinical relapse. Median
follow-up of the study children was 6.7 months (IQR 3.3–8.9 months). Two children (1.6%) developed
mild sequelae (angular deformity).
4. Discussion
Availability of local data is important in order to optimize local therapeutic protocols [10]. To our
knowledge this is one of the largest studies on paediatric AHOM performed in Europe. Similar
cohort studies have been previously conducted in Spain [14], and France [21], as well as in other
extra-European countries including Israel [22], Thailand [23], Australia [3], and the United States [24].
Results from these studies highlight differences in local microbiological data which may be, at least
partly, influenced not only by geographical variations, but also by the availability of sophisticated
microbiological/PCR assays. As an example, the reported prevalence of Kingella kingae infection ranges
from 0% up to 82% children with osteo-articular infection [25,26], probably because its identification is
challenging and requires targeted aerobic blood culture vials or real-time PCR technique.
Our study confirms epidemiological data previously well described in literature [5]: AHOM is
more commonly reported in males and in young children, it more frequently involves the lower limb
and long bones, and the patient’s history is commonly positive for a recent trauma or a febrile episode.
In our dataset fever at admission was present only in 45% of children. This finding is in accordance
with that one reported by Dartnell et al. [17] who observed fever as the presenting symptom only
in 61.7% of children, while pain and swelling and erythema where present in 81.1% and 70% of the
cases, respectively. We also comfirmed that WBC has a low sensitivity compared to ESR and CRP.
Similarly, in other studies, leukocytosis has been reported only in 36% of children, but increased ESR
was observed in 91% of children and CRP in 81% of them [27]. As expected, we observed a low
sensitivity of X-ray imaging [28] and US [4].
Microbiological identification of the causative pathogen in our dataset was consistent with
previous results [14]: a microorganism was identified bin more than one third of cases. The sensitivity
of blood and pus culture was 32.4% and 46.4%, respectively. The sensitivity of the PCR assay was
only 3.6% on blood sample and reached 64.0% on pus/biopsy sample, underlying the importance of
performing PCR assay on pus/biopsy specimens.
S. aureus was the most commonly identified etiological pathogen, but no MRSA strain was isolated.
This result is in contrast with data reported from the United States [8,29] but is consistent with other
European findings [14,16,17,30]. It should be noticed that, in our dataset 10.0% S. aureus strains were
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PVL producers. Both cases were complicated. In Europe PVL producing S. aureus, even if most
commonly methicillin sensitive, has been associated with more severe infections, therefore treatment
should be aggressive and should include an antibiotic with antitoxin effect (i.e., clindamycin, linezolid,
or rifampicin) [9,31]. We observed that commonly prescribed antibiotics in our dataset included
glycopeptides, carbapenems, or quinolones or a double therapy with cephalosporin plus one penicillin.
Since these regimens are not recommended as first line treatment for AHOM in children, interventions
aimed to promote a more appropriate use of antibiotics in our setting are needed.
Our study has several limitations, due to its retrospective nature. Moreover, only 59.5% of the
children underwent at least one microbiological investigation before commencing an antibiotic therapy
and follow-up was limited to 6 months. Another limitation is that although PCR16S is commonly
used in our Center to identify bacterial infection, a specific real time PCR for K. kingae is not available.
This may have led to an underestimation of K. kingae infections.
5. Conclusions
Complications occur frequently in children with AHOM and are strongly related to S. aureus
infection. In this study microbiological diagnosis was obtained in over one third of cases. Empiric
treatment targeting methicillin-sensitive Staphylococcus aureus seems to be justified by available
microbiological data.
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